You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Submits Comments on ClinicalTrials.gov Expansion

<p>
The Biotechnology Industry Organization (BIO) thanks the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) for the opportunity to submit comments on the Notice of Proposed Rulemaking (NPRM) entitled Clinical Trials Registration and Results Submission.</p>

 The Biotechnology Industry Organization (BIO) thanks the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) for the opportunity to submit comments on the Notice of Proposed Rulemaking (NPRM) entitled Clinical Trials Registration and Results Submission.

BIO’s members are committed to improving health through the development of innovative therapies. We strongly support research that aims to improve human health through better drug development and recognize that the responsibility in sharing our clinical trial data can help to advance research while reinforcing public confidence in the safety and efficacy in our medicines. Efforts to increase the availability of accurate, scientific evidence will arm patients, clinical decision makers, and scientific researchers with the best available information to help assess the relative clinical benefits and risks of a given treatment.